An Exploratory Single Site, Open Label, Randomized, Controlled Study to Evaluate Plasma Vascular Endothelial Growth Factor Levels After Intravitreal Injection of Ranibizumab (Lucentis) and Conbercept (Langmu) for nAMD
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Ranibizumab (Primary) ; Conbercept
- Indications Wet age-related macular degeneration
- Focus Pharmacodynamics
- Acronyms RELIANCE
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2016 Status changed from recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.